SAT0377 Long-Term Safety and Tolerability of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: A Phase 3, Randomized, Controlled TrialAde Adebajo, Jacob Aelion, A. Wells et al.|Annals of the Rheumatic Diseases|2014Cited by 2
AB0905 Long-term (5-YEAR) efficacy and safety of apremilast monotherapy in dmard-naÏve subjects with active psoriatic arthritisA. Wells, Jacob Aelion, B. Guérette et al.|Annals of the Rheumatic Diseases|2018Cited by 0